OGT announced the launch of a new next-generation sequencing (NGS) panel for Measurable Residual Disease (MRD) - the SureSeq Myeloid MRD Plus NGS Panel. The panel detects ultra-low frequency variants in key MRD-associated biomarkers in acute myeloid leukemia (AML).
This means users of this panel can obtain detailed genomic information, to provide an earlier and more complete picture of their sample's MRD status.
With targeted coverage of 16 biomarkers associated with AML, including FLT3 and NPM1, the SureSeq Myeloid MRD Plus NGS Panel is optimized for MRD characterization. Users benefit from robust detection of complex and challenging mutations such as FLT3 internal tandem duplications (ITDs) exceeding 300 base pairs, to ensure they can obtain comprehensive genomic insights from their samples. Additionally, its focused design enables high-precision variant detection without the increased sequencing costs typically associated with broader panels and, by leveraging SureSeq’s refined bait design strategy, the panel achieves exceptional sensitivity, detecting variants at allele frequencies as low as 0.01%.
Complementing the panel is Interpret, OGT’s powerful bioinformatics solution which includes longitudinal visualization of MRD dynamics over time - including SNVs, indels and ITDs. Available as a secure cloud-based platform or local installation, Interpret offers user-friendly pre-configured analysis pipelines which streamline laboratory workflows and accelerate implementation. Additionally, customization options allow users to tailor their analysis to meet their specific clinical research needs.
Read OGT's announcement here
